Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers

Frank Witter, Florence Barouki, Diane Griffin, Paul Nadler, Amina Woods, Debra Wood, Paul Lietman

Research output: Contribution to journalArticle

Abstract

The kinetics of the antiviral effect of intramuscular and intravenous injections of recombinant human interferon α2a were investigated in healthy volunteers. Cohorts of eight to 11 subjects received single intramuscular injections of either 0.3 × 106, 3 × 106, or 18 × 106 U or an intravenous infusion of 18 × 106 U over 30 minutes. Serial samples of peripheral blood mononuclear cells were analyzed for antiviral effects including both (2′-5′) oligoadenylate synthetase activity and resistance to vesicular stomatitis virus infection in vitro. A dose-response relationship was established between recombinant human interferon a2, dose and both vesicular stomatitis virus resistance and (2′-5′) oligoadenylate synthetase activity. At the 0.3 x 106U dose an antiviral effect occurred without clinical side effects. The presence of clinical side effects is not necessary for an antiviral effect.

Original languageEnglish (US)
Pages (from-to)567-575
Number of pages9
JournalClinical pharmacology and therapeutics
Volume42
Issue number5
DOIs
StatePublished - Nov 1987

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers'. Together they form a unique fingerprint.

  • Cite this